Regorafenib information

Regorafenib
Clinical data
Trade names	Stivarga, Regonix
Other names	BAY 73-4506
AHFS/Drugs.com	Monograph
MedlinePlus	a613004
License data	EU EMA: by INN; US DailyMed: Regorafenib;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
ATC code	L01EX05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: WARNINGRx-only;
Pharmacokinetic data
Bioavailability	69-83%
Protein binding	99.5%
Metabolism	Hepatic (UGT1A9-mediated)
Elimination half-life	20-30 hours
Excretion	Feces (71%), urine (19%)
Identifiers
	IUPAC name 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide hydrate;
CAS Number	755037-03-7;
PubChem CID	11167602;
DrugBank	DB08896;
ChemSpider	9342697;
UNII	24T2A1DOYB;
KEGG	D10138;
ChEBI	CHEBI:68647 ;
ChEMBL	ChEMBL1946170;
CompTox Dashboard (EPA)	DTXSID60226441 ;
ECHA InfoCard	100.248.939
Chemical and physical data
Formula	C21H15ClF4N4O3
Molar mass	482.82 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC(=O)c1cc(ccn1)Oc2ccc(c(c2)F)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl;
	InChI InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32); Key:FNHKPVJBJVTLMP-UHFFFAOYSA-N;

Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types.^[2] By 2015 it had two US approvals for advanced cancers.

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ "Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009". Retrieved 2009-09-19.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

[2] "Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009". Retrieved 2009-09-19.

Regorafenib information

and 27 Related for: Regorafenib information

Regorafenib

Avapritinib

Fruquintinib

Onyx Pharmaceuticals

Beacon Pharmaceuticals

Insulin

Testosterone

Zanzalintinib

Erythropoietin

Bayer

Cerebrolysin

Trastuzumab deruxtecan

Mosunetuzumab

Dexamethasone

Gastrointestinal stromal tumor

Epidermal growth factor

Faricimab

Nintedanib

Dabrafenib

Amitriptyline

Dasatinib

Trifluridine

Adult neurogenesis

Transforming growth factor

Neurotrophic factors

Elranatamab

Nerve growth factor